BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

586 related articles for article (PubMed ID: 24710217)

  • 21. Targeted sequencing to identify genetic alterations and prognostic markers in pediatric T-cell acute lymphoblastic leukemia.
    Chang YH; Yu CH; Jou ST; Lin CY; Lin KH; Lu MY; Wu KH; Chang HH; Lin DT; Lin SW; Chen HY; Yang YL
    Sci Rep; 2021 Jan; 11(1):769. PubMed ID: 33436855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia.
    López C; Bergmann AK; Paul U; Murga Penas EM; Nagel I; Betts MJ; Johansson P; Ritgen M; Baumann T; Aymerich M; Jayne S; Russell RB; Campo E; Dyer MJ; Dürig J; Siebert R
    Br J Haematol; 2016 Apr; 173(2):265-73. PubMed ID: 26917488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response.
    Núñez FJ; Mendez FM; Kadiyala P; Alghamri MS; Savelieff MG; Garcia-Fabiani MB; Haase S; Koschmann C; Calinescu AA; Kamran N; Saxena M; Patel R; Carney S; Guo MZ; Edwards M; Ljungman M; Qin T; Sartor MA; Tagett R; Venneti S; Brosnan-Cashman J; Meeker A; Gorbunova V; Zhao L; Kremer DM; Zhang L; Lyssiotis CA; Jones L; Herting CJ; Ross JL; Hambardzumyan D; Hervey-Jumper S; Figueroa ME; Lowenstein PR; Castro MG
    Sci Transl Med; 2019 Feb; 11(479):. PubMed ID: 30760578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deleterious point mutations in T-cell acute lymphoblastic leukemia: Mechanistic insights into leukemogenesis.
    Roy U; Raghavan SC
    Int J Cancer; 2021 Sep; 149(6):1210-1220. PubMed ID: 33634864
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epigenetic mechanisms in paediatric brain tumours: regulators lose control.
    Badodi S; Marino S
    Biochem Soc Trans; 2022 Feb; 50(1):167-185. PubMed ID: 35076654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. UTX inhibition as selective epigenetic therapy against TAL1-driven T-cell acute lymphoblastic leukemia.
    Benyoucef A; Palii CG; Wang C; Porter CJ; Chu A; Dai F; Tremblay V; Rakopoulos P; Singh K; Huang S; Pflumio F; Hébert J; Couture JF; Perkins TJ; Ge K; Dilworth FJ; Brand M
    Genes Dev; 2016 Mar; 30(5):508-21. PubMed ID: 26944678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas.
    Salloum R; McConechy MK; Mikael LG; Fuller C; Drissi R; DeWire M; Nikbakht H; De Jay N; Yang X; Boue D; Chow LML; Finlay JL; Gayden T; Karamchandani J; Hummel TR; Olshefski R; Osorio DS; Stevenson C; Kleinman CL; Majewski J; Fouladi M; Jabado N
    Acta Neuropathol Commun; 2017 Oct; 5(1):78. PubMed ID: 29084603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3.
    Wiese M; Schill F; Sturm D; Pfister S; Hulleman E; Johnsen SA; Kramm CM
    Klin Padiatr; 2016 Apr; 228(3):113-7. PubMed ID: 27135271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. "Monoallelic germline methylation and sequence variant in the promoter of the RB1 gene: a possible constitutive epimutation in hereditary retinoblastoma".
    Quiñonez-Silva G; Dávalos-Salas M; Recillas-Targa F; Ostrosky-Wegman P; Aranda DA; Benítez-Bribiesca L
    Clin Epigenetics; 2016; 8():1. PubMed ID: 26753011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A system for detecting high impact-low frequency mutations in primary tumors and metastases.
    Anjanappa M; Hao Y; Simpson ER; Bhat-Nakshatri P; Nelson JB; Tersey SA; Mirmira RG; Cohen-Gadol AA; Saadatzadeh MR; Li L; Fang F; Nephew KP; Miller KD; Liu Y; Nakshatri H
    Oncogene; 2018 Jan; 37(2):185-196. PubMed ID: 28892047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The epigenetic landscape of T-cell acute lymphoblastic leukemia.
    Van der Meulen J; Van Roy N; Van Vlierberghe P; Speleman F
    Int J Biochem Cell Biol; 2014 Aug; 53():547-57. PubMed ID: 24786297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas.
    Schäfer S; Behling F; Skardelly M; Koch M; Ott I; Paulsen F; Tabatabai G; Schittenhelm J
    Neuropathol Appl Neurobiol; 2018 Feb; 44(2):207-223. PubMed ID: 29053887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression Profile Analysis of Zinc Transporters (ZIP4, ZIP9, ZIP11, ZnT9) in Gliomas and their Correlation with IDH1 Mutation Status.
    Kang X; Chen R; Zhang J; Li G; Dai PG; Chen C; Wang HJ
    Asian Pac J Cancer Prev; 2015; 16(8):3355-60. PubMed ID: 25921144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma.
    Dubuc AM; Remke M; Korshunov A; Northcott PA; Zhan SH; Mendez-Lago M; Kool M; Jones DT; Unterberger A; Morrissy AS; Shih D; Peacock J; Ramaswamy V; Rolider A; Wang X; Witt H; Hielscher T; Hawkins C; Vibhakar R; Croul S; Rutka JT; Weiss WA; Jones SJ; Eberhart CG; Marra MA; Pfister SM; Taylor MD
    Acta Neuropathol; 2013 Mar; 125(3):373-84. PubMed ID: 23184418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.
    Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT
    Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours.
    Haque F; Varlet P; Puntonet J; Storer L; Bountali A; Rahman R; Grill J; Carcaboso AM; Jones C; Layfield R; Grundy RG
    Acta Neuropathol Commun; 2017 Jun; 5(1):45. PubMed ID: 28587626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genome-wide network analysis of Wnt signaling in three pediatric cancers.
    Bao J; Lee HJ; Zheng JJ
    Sci Rep; 2013 Oct; 3():2969. PubMed ID: 24132329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unraveling the glioma epigenome: from molecular mechanisms to novel biomarkers and therapeutic targets.
    Malzkorn B; Wolter M; Riemenschneider MJ; Reifenberger G
    Brain Pathol; 2011 Nov; 21(6):619-32. PubMed ID: 21939466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetics and epigenetics of human retinoblastoma.
    Benavente CA; Dyer MA
    Annu Rev Pathol; 2015; 10():547-62. PubMed ID: 25621664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncogenes and anti-oncogenes in human central nervous system tumors.
    Batra SK; Rasheed BK; Bigner SH; Bigner DD
    Lab Invest; 1994 Nov; 71(5):621-37. PubMed ID: 7967518
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.